Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

3078 - Pazopanib in advanced or metastatic synovial sarcoma: the Gustave Roussy experience

Date

22 Oct 2018

Session

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

Topics

Cytotoxic Therapy

Tumour Site

Sarcoma

Presenters

Marine Sroussi

Citation

Annals of Oncology (2018) 29 (suppl_8): viii576-viii595. 10.1093/annonc/mdy299

Authors

M. Sroussi1, S. De Percin1, A.M. Grecea1, M.A. Benderra1, M. Velev1, S. Akla1, N. Lezghed1, S. Dumont1, C. Le Péchoux2, C. Honore3, L. Haddag4, M. Faron3, P. Terrier5, O. Mir1, A. Le Cesne1

Author affiliations

  • 1 Medical Oncology Department, Institut Gustave Roussy, 94800 - Villejuif/FR
  • 2 Radiation oncology Department, Institut Gustave Roussy, 94800 - Villejuif/FR
  • 3 Surgery Department, Institut Gustave Roussy, 94800 - Villejuif/FR
  • 4 Radiology Department, Institut Gustave Roussy, 94800 - Villejuif/FR
  • 5 Pathology Department, Institut Gustave Roussy, 94800 - Villejuif/FR
More

Abstract 3078

Background

Synovial sarcoma (SS) is a rare malignancy usually considered as sensitive to chemotherapy (CT) based on anthracyclins and ifosfamide. Therapeutic options are limited and prognosis of advanced or metastatic SS (a/mSS) remains dismal. Since approval of pazopanib in advanced soft tissue sarcomas (STS), very few data were reported on the activity of pazopanib in a/mSS.

Methods

We retrospectively reviewed all patients (pts) treated with pazopanib for a/mSS in our institution. The histological diagnosis was confirmed by a referral pathologist within the French Sarcoma Group. Data were obtained from medical records. Radiological response was assessed by CT-scan according to RECIST 1.1. Adverse events were graded according to the Common Terminology Criteria for Adverse Events of the National Cancer Institute 4.03. The aim of this study was to evaluate the activity of pazopanib in a/mSS.

Results

From December 2006 to April 2018, 16 pts with a/mSS of extremities (10 pts), trunk (5 pts) or head and neck region (1 patient) were treated with pazopanib from 400 mg to 800 mg daily dose. Median age was 40 years old (range: 24-69). Pts received a median of 2 prior lines of doxorubicin-based CT in all but one case. Thirty-one per cent of pts received pazopanib in 2nd line therapy and 69% in subsequent lines. Before treatment, 15 pts (94%) had distant metastases (lung in 94%, bone in 25%, associated with local recurrence in 20%) and 1 patient (6%) had unresectable local recurrence. A clinical benefit was observed in 87.5% of pts: 7 (43%) experienced a partial response and 7 (43%) a stable disease. Two pts progressed rapidly during treatment. Two pts definitively interrupted pazopanib due to grade 3 sepsis or hemoptysia. The dose was reduced for 2 pts due to diarrhea and hematuria. On April 2018, 6 patients were still on treatment. The median progression free survival (mPFS) was 6.5 months (1-17+). After a median follow-up of 8.5 months, the median overall survival was not reached.

Conclusions

Pazopanib showed significant clinical activity in a/mSS along with manageable toxicity profile. We observed a prolonged mPFS compared with other subtypes of STS. These results need to be confirmed in prospective trials dedicated to this histological subtype of STS.

Clinical trial identification

Legal entity responsible for the study

Institut Gustave Roussy.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.